Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 3/2017

Open Access 01-09-2017 | Review

Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II

Authors: Nancy F. Crum-Cianflone, Eva Sullivan

Published in: Infectious Diseases and Therapy | Issue 3/2017

Login to get access

Abstract

Vaccination is a critical component for ensuring the ongoing health HIV-infected adults. Since this group may have reduced immune responses and shorter durations of protection post-vaccination, HIV-specific guidelines have been published. This review article provides a comprehensive discussion of the current guidelines and evidence-based data for vaccinating HIV-infected adults, including data on dosing schedules, immunogenicity studies, and safety. In the current paper, part II of the review, live vaccines, as well as vaccines for travelers and specific occupational groups, will be discussed.
Literature
1.
2.
3.
4.
Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB, On behalf of the Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med. 2017;166:209–19.PubMedCrossRef
5.
Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://​aidsinfo.​nih.​gov/​contentfiles/​lvguidelines/​adult_​OI.​pdf. Accessed 30 Mar 2017.
6.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309–18.PubMedCrossRef
7.
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:e1–34.PubMedCrossRef
8.
9.
Frésard A, Gagneux-Brunon A, Lucht F, Botelho-Nevers E, Launay O. Immunization of HIV-infected adult patients—French recommendations. Hum Vaccin Immunother. 2016;12:2729–41.PubMedPubMedCentralCrossRef
10.
Kramer JM, LaRussa P, Tsai WC, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics. 2001;108:E39.PubMedCrossRef
11.
Maves RC, Tripp MS, Dell TG, et al. Disseminated vaccine-strain varicella as initial presentation of the acquired immunodeficiency syndrome: a case report and review of the literature. J Clin Virol. 2014;59:63–6.PubMedCrossRef
12.
Veenstra J, van Praag RM, Krol A, et al. Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS. 1996;10:393–9.PubMedCrossRef
13.
Moanna A, Rimland D. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era. Clin Infect Dis. 2013;57:122–5.PubMedCrossRef
14.
Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr. 2012;61:203–7.PubMedPubMedCentralCrossRef
15.
Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015;60:1269–77.PubMedCrossRef
16.
Wallace MR, Hooper DG, Pyne JM, Graves SJ, Malone JL. Varicella immunity and clinical disease in HIV-infected adults. South Med J. 1994;87:74–6.PubMedCrossRef
17.
Molton J, Smith C, Chaytor S, et al. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect. 2010;61:73–80.PubMedCrossRef
18.
Aziz M, Kessler H, Huhn G. Providers’ lack of knowledge about herpes zoster in HIV-infected patients is among barriers to herpes zoster vaccination. Int J STD AIDS. 2013;24:433–9.PubMedCrossRef
19.
Souty C, Boos E, Turbelin C, et al. Vaccination against varicella as post-exposure prophylaxis in adults: a quantitative assessment. Vaccine. 2015;33:446–50.PubMedCrossRef
20.
Son M, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Disl. 2010;201:1806–10.CrossRef
21.
Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305–10.PubMedCrossRef
22.
Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis. 2006;194:247–55.PubMedCrossRef
23.
Taweesith W, Puthanakit T, Kowitdamrong E, et al. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2011;30:320–4.PubMedCrossRef
24.
Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin. 2010;6:318–21.PubMedCrossRef
25.
Morrison VA, Johnson GR, Schmader KE, Shingles Prevention Study Group, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900–9.PubMedCrossRef
26.
Barnabas RV, Baeten JM, Lingappa JR, Partners in Prevention HSV/HIV Transmission Study Team, et al. Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: results of a randomized clinical trial. J Infect Dis. 2016;213:551–5.PubMedCrossRef
27.
Lal H, Cunningham AL, Godeaux O, ZOE-50 Study Group, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.PubMedCrossRef
28.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–31.PubMedCrossRef
29.
Berkowitz EM, Moyle G, Stellbrink HJ, Zoster-015 HZ/su Study Group, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279–87.PubMed
30.
Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375–85.PubMedCrossRef
31.
Oxman MN, Levin MJ, Johnson GR, Shingles Prevention Study Group, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.PubMedCrossRef
32.
Benson CA, Hua L, Anderson JW, et al for the ACTG A5247 Team. Zostavax is generally safe and immunogenic in HIV + adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial. 19th CROI, Seattle, 5–8 Mar 2012. Oral abstract 96.
33.
Shafran SD. Live attenuated herpes zoster vaccine for HIV-infected adults. HIV Med. 2016;17:305–10.PubMedCrossRef
34.
Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008;358:1580–9.PubMedCrossRef
35.
Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA. 2016;315:1149–58.PubMedPubMedCentralCrossRef
36.
Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267:1237–41.PubMedCrossRef
37.
Angel JB, Walpita P, Lerch RA, et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med. 1998;129:104–6.PubMedCrossRef
38.
Centers for Disease Control and Prevention (CDC). Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. Morb Mortal Wkly Rep. 1996;45:603–6.
39.
Grabmeier-Pfistershammer K, Poeppl W, Herkner H, et al. High need for MMR vaccination in HIV infected adults in Austria. Vaccine. 2014;32:6020–3.PubMedCrossRef
40.
Llenas-García J, Rubio R, Hernando A, Arrazola P, Pulido F. Do HIV-positive adult immigrants need to be screened for measles–mumps–rubella and varicella zoster virus immunization? AIDS Care. 2013;25:980–9.PubMedCrossRef
41.
Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1992;11:1008–14.PubMedCrossRef
42.
Wallace MR, Hooper DG, Graves SJ, Malone JL. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine. 1994;12:1222–4.PubMedCrossRef
43.
Kemper CA, Zolopa AR, Hamilton JR, Fenstersheib M, Bhatia G, Deresinski SC. Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity. AIDS. 1992;6:1321–5.PubMedCrossRef
44.
Singh HK, Chiu YL, Wilkin T. Measles, mumps, and rubella serostatus and response to MMR vaccination among HIV-infected adults. AIDS Patient Care STDS. 2015;29:461–4.PubMedCrossRef
45.
Sprauer MA, Markowitz LE, Nicholson JK, et al. Response of human immunodeficiency virus-infected adults to measles–rubella vaccination. J Acquir Immune Defic Syndr. 1993;6:1013–6.PubMed
46.
Belaunzarán-Zamudio PF, García-León ML, Wong-Chew RM, et al. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine. 2009;27:7059–64.PubMedCrossRef
47.
Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis. 2007;45:637–42.PubMedCrossRef
48.
Abzug MJ, Qin M, Levin MJ, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams, et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2012;206:512–22.PubMedPubMedCentralCrossRef
49.
Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis. 2010;50:1415–8.PubMedCrossRef
50.
Stermole BM, Grandits GA, Roediger MP, Clark BM, Ganesan A, Weintrob AC, Crum-Cianflone NF, Ferguson TM, Macalino GE, Landrum ML. Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults. Vaccine. 2011;29:2874–80.PubMedPubMedCentralCrossRef
51.
Franco-Paredes C, Hidron A, Tellez I, Lesesne J, Del Rio C. HIV infection and travel: pretravel recommendations and health-related risks. Top HIV Med. 2009;17:2–11.PubMed
52.
53.
54.
Khetsuriani N, Helfand R, Pallansch M, et al. Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in Kenya. BMC Infect Dis. 2009;9:1–8.CrossRef
55.
Gouandjika-Vasilache I, Akoua-Koffi C, Begaud E, Dosseh A. No evidence of prolonged enterovirus excretion in HIV-seropositive patients. Trop Med Int Health. 2005;10:743–7.PubMedCrossRef
56.
Ion-Nedelcu N, Dobrescu A, Strebel PM, Sutter RW. Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet. 1994;343:51–2.PubMedCrossRef
57.
58.
Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:1197–203.PubMedCrossRef
59.
Vardinon N, Handsher R, Burke M, Zacut V, Yust I. Poliovirus vaccination responses in HIV-infected patients: correlation with T4 cell counts. J Infect Dis. 1990;162:238–41.PubMedCrossRef
60.
Barbi M, Biffi MR, Binda S, et al. Immunization in children with HIV seropositivity at birth: antibody response to polio vaccine and tetanus toxoid. AIDS. 1992;6:1465–9.PubMedCrossRef
61.
Gnanashanmugam D, Troy SB, Musingwini G, et al. Immunologic response to oral polio vaccine in human immunodeficiency virus-infected and uninfected Zimbabwean children. Pediatr Infect Dis J. 2012;31:176–80.PubMedCrossRef
62.
Troy SB, Kouiavaskaia D, Siik J, et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults. J Infect Dis. 2015;211:1969–76.PubMedPubMedCentralCrossRef
63.
Mathisen GE, Allen AD. Inactivated polio vaccine hyperimmunization in adults with HIV disease: a placebo-controlled study. AIDS. 1992;6:737–8.PubMedCrossRef
64.
Gordon MA, Kankwatira AM, Mwafulirwa G, et al. Invasive non-typhoid salmonellae establish systemic intracellular infection in HIV-infected adults: an emerging disease pathogenesis. Clin Infect Dis. 2010;50:953–62.PubMedCrossRef
65.
66.
Feasey NA, Houston A, Mukaka M, et al. A reduction in adult blood stream infection and case fatality at a large African hospital following antiretroviral therapy roll-out. PLoS ONE. 2014;9:e92226.PubMedPubMedCentralCrossRef
67.
Jackson BR, Iqbal S, Mahon M. Updated recommendations for the use of typhoid vaccine—Advisory Committee on Immunization Practices, United States, 2015. Morb Mortal Wkly Rep. 2015;64:305–8.
68.
Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine. 1999;17:2941–5.PubMedCrossRef
69.
Banda R, Yambayama V, Lalusha BD, et al. Safety of live, attenuated oral vaccines in HIV-infected Zambian adults-oral vaccines in HIV. Vaccine. 2012;30:5656–60.PubMedPubMedCentralCrossRef
70.
71.
Smith DS. Travel medicine and vaccines for HIV-infected travelers. HIV Travel. 2012;20:111–5.
72.
Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;doi:10.1002/14651858.CD010929.pub2.
73.
Sidibe M, Yactayo S, Kalle A, et al. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg. 2012;106:437–44.PubMedCrossRef
74.
Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1997;16:1177–9.PubMedCrossRef
75.
Pistone T, Verdière CH, Receveur MC, Ezzedine K, Lafon ME, Malvy D. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res. 2010;8:461–6.PubMedCrossRef
76.
Tattevin P, Depatureaux AG, Chapplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS. 2004;18:825–7.PubMedCrossRef
77.
Pacanowski J, Lacombe K, Campa P, et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr. 2012;59:360–7.PubMedCrossRef
78.
Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659–66.PubMedCrossRef
79.
Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85:131–4.PubMed
80.
81.
Pancharoen C, Thisyakorn U, Tantawichien T, Jaijaroensup W, Khawplod P, Wilde H. Failure of pre- and postexposure rabies vaccinations in a child infected with HIV. Scand J Infect Dis. 2001;33:390–1.PubMedCrossRef
82.
Thisyakorn U, Pancharoen C, Wilde H. Immunologic and virologic evaluation of HIV-1-infected children after rabies vaccination. Vaccine. 2001;19:1534–7.PubMedCrossRef
83.
Thisyakorn U, Pancharoen C, Ruxrungtham K, et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2000;30:218.PubMedCrossRef
84.
Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis. 2001;33:E122–4.PubMedCrossRef
85.
Jaijaroensup W, Tantawichien T, Khawplod P, Tepsumethanon S, Wilde H. Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin Infect Dis. 1999;28:913–4.PubMedCrossRef
86.
Gelinck LB, Jol-van der Zijde CM, Jansen-Hoogendijk AM, et al. Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART. AIDS. 2009;23:2451–8.PubMedCrossRef
87.
Azzoni L, Foulkes AS, Firnhaber C, Yin X, Xiang ZQ, Li Y, Stevens W, Gross R, Ertl HC, Sanne I, Montaner LJ. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012;26:1355–62.PubMedPubMedCentralCrossRef
88.
Sirikwin S, Likanonsakul S, Waradejwinyoo S, et al. Antibody response to an eight-site intradermal rabies vaccination in patients infected with human immunodeficiency virus. Vaccine. 2009;27:4350–4.PubMedCrossRef
89.
Rojanasuphot S, Shaffer N, Chotpitayasunondh T, et al. Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian J Trop Med Public Health. 1998;29:443–50.PubMed
90.
Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine. 2007;25:8257–61.PubMedCrossRef
91.
Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V. A 3-year follow-up of antibody response in HIV-infected children with immune recovery vaccinated with inactivated Japanese encephalitis vaccine. Vaccine. 2010;28:5900–2.PubMedCrossRef
92.
Chokephaibulkit K, Plipat N, Yoksan S, et al. A comparative study of the serological response to Japanese encephalitis vaccine in HIV-infected and uninfected Thai children. Vaccine. 2010;28:3563–6.PubMedCrossRef
93.
von Seidlein L, Wang XY, Macuamule A, et al. Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique. Trop Med Int Health. 2008;13:683–8.CrossRef
94.
Lucas ME, Deen JL, von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med. 2005;352:757–67.PubMedCrossRef
95.
Lewis DJ, Gilks CF, Ojoo S, et al. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS. 1994;8:779–85.PubMedCrossRef
96.
Ivers LC, Charles RC, Hilaire IJ, et al. Immunogenicity of the bivalent oral cholera vaccine Shanchol in Haitian adults with HIV infection. J Infect Dis. 2015;212:779–83.PubMedPubMedCentralCrossRef
97.
Perry RT, Plowe CV, Koumare B, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ. 1998;76:63–71.PubMedPubMedCentral
98.
Westrop SJ, Moyle G, Jackson A, Nelson M, Mandalia S, Imami N. CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection. Mol Med. 2012;18:1240–8.PubMedPubMedCentralCrossRef
99.
Amicizia D, Domnich A, Panatto D, et al. Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Hum Vaccin Immunother. 2013;9:1163–71.PubMedPubMedCentralCrossRef
100.
Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis. 2008;197:266–9.PubMedCrossRef
101.
Panasiuk B, Prokopowicz D, Panasiuk A. Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection. 2003;31:45–6.PubMedCrossRef
102.
Wolf HM, Pum M, Jáger R, István L, Mannhalter JW, Eibl MM. Cellular and humoral immune responses in haemophiliacs after vaccination against tick-borne encephalitis. Br J Haematol. 1992;82:374–83.PubMedCrossRef
103.
Wright JG, Quinn CP, Shadomy S, Messonnier N, Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. Recomm Rep. 2010;59:1–30.
104.
Bartlett JG. Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome. Clin Infect Dis. 2003;36:468–71.PubMedCrossRef
105.
Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. Recomm Rep. 2015;64:1–26.CrossRef
106.
Tasker SA, Schnepf GA, Lim M, US Department of Defense Tri-Service AIDS Clinical Consortium, et al. Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis. 2004;38:1320–2.PubMedCrossRef
107.
Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:673–6.PubMedCrossRef
108.
Greenberg RN, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis. 2013;207:749–58.PubMedCrossRef
109.
Cosma A, Nagaraj R, Staib C, et al. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART. AIDS Res Hum Retrovir. 2007;23:782–93.PubMedCrossRef
110.
Overton ET, Stapleton J, Frank I, et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naïve and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015;2:ofv040.PubMedPubMedCentralCrossRef
111.
Collins S, Ramsay M, Campbell H, Slack MP, Ladhani SN. Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis. 2013;57:1715–21.PubMedCrossRef
112.
Steinhart R, Reingold AL, Taylor F, Anderson G, Wenger JD. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA. 1992;268:3350–2.PubMedCrossRef
113.
Steinhoff MC, Auerbach BS, Nelson KE, et al. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med. 1991;325:1837–42.PubMedCrossRef
114.
Dockrell DH, Poland GA, Steckelberg JM, Wollan PC, Strickland SR, Pomeroy C. Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine. 1999;17:2779–85.PubMedCrossRef
115.
De Sousa dos Santos S, Lopes MH, Simonsen V, Caiaffa Filho HH. Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus. AIDS Res Hum Retrovir. 2004;20:493–6.PubMedCrossRef
116.
117.
118.
Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58:470–80.PubMedCrossRef
119.
Centers for Disease Control (CDC). Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. Morb Mortal Wkly Rep. 1985;34:227–8.
120.
Boudes P, Sobel A, Deforges L, Leblic E. Disseminated Mycobacterium bovis infection from BCG vaccination and HIV infection. JAMA. 1989;262:2386.PubMedCrossRef
121.
Vera JH, Hill SC, Rubinstein L. Bacille Calmette–Guerin disease following Bacille Calmette–Guerin vaccination of an HIV-infected health-care worker. Int J STD AIDS. 2012;23:e1–2.PubMedCrossRef
122.
Azzopardi P, Bennett CM, Graham SM, Duke T. Bacille Calmette–Guérin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis. 2009;13:1331–44.PubMed
123.
Reynes J, Perez C, Lamaury I, Janbon F, Bertrand A. Bacille Calmette–Guérin adenitis 30 years after immunization in a patient with AIDS. J Infect Dis. 1989;160:727.PubMedCrossRef
124.
Armbruster C, Junker W, Vetter N, Jaksch G. Disseminated bacille Calmette–Guérin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis. 1990;162:1216.PubMedCrossRef
125.
Lumb R, Shaw D. Mycobacterium bovis (BCG) vaccination. Progressive disease in a patient asymptomatically infected with the human immunodeficiency virus. Med J Aust. 1992;156:286–7.PubMed
126.
Smith E, Thybo S, Bennedsen J. Infection with Mycobacterium bovis in a patient with AIDS: a late complication of BCG vaccination. Scand J Infect Dis. 1992;24:109–10.PubMedCrossRef
Metadata
Title
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II
Authors
Nancy F. Crum-Cianflone
Eva Sullivan
Publication date
01-09-2017
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 3/2017
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-017-0165-y

Other articles of this Issue 3/2017

Infectious Diseases and Therapy 3/2017 Go to the issue

Review

A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective

Original Research

Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States

Original Research

A Survey of Patients’ Perspectives on Outpatient HIV Care in the Netherlands

Original Research

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies

Review

Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases

Original Research

In vitro and In vivo Activity of Theaflavin–Epicatechin Combinations versus Multidrug-Resistant Acinetobacter baumannii
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits